FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Γ

			Washington, D.C. 20549	OMB APPROVAL				
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See		STATEME	NT OF CHANGES IN BENEFICIAL OWNI	ERSHIP	OMB Number: Estimated average b hours per response:			
Instruction 1(k		File	d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940		liours per response.	0.3		
1	Iress of Reporting P	erson*	2. Issuer Name and Ticker or Trading Symbol Novus Therapeutics, Inc. [NVUS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
McBride Jo	<u>hn S.</u>		wovus merapeutics, mc. [NV05]	X Director	100	% Owner		
(Last) C/O NOVUS	(First) THERAPEUTIC	(Middle) S, INC.	3. Date of Earliest Transaction (Month/Day/Year) 06/13/2018	- Officer (gi below)		her (specify low)		
19900 MACA	RTHUR BLVD.,	SUITE 550	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)					I by One Reporting P	Person		
IRVINE	CA	92612		Form filed Person	I by More than One F	Reporting		
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table 1 Hori Bernaure Ceournes Adquired, Disposed of, of Berlenblary Office												
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$6.18	06/13/2018		A		9,100		06/13/2019	06/13/2028	Common Stock	9,100	\$0.00	9,100	D	

Explanation of Responses:

Remarks:

/s/ Ryan A. Murr, as attorneyin-fact for John S. McBride

06/14/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.